> Detailanzeige

Stracke, Sylvia; Lange, Sandra; Bornmann, Sarah; Kock, Holger; Schulze, Lara; Klinger-König, Johanna; Böhm, Susanne; Vogelgesang, Antje; von Podewils, Felix; Föel, Agnes; Gross, Stefan; Wenzel, Katrin; Wallukat, Gerd; Prüss, Harald; Dressel, Alexander; Kunze, Rudolf; Grabe, Hans J.; Langner, Sönke; Dörr, Marcus

Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Immunoadsorption for Treatment of Patients with Suspected Alzheimer Dementia and Agonistic Autoantibodies against Alpha1a-Adrenoceptor—Rationale and Design of the IMAD Pilot Study
  • Beteiligte: Stracke, Sylvia; Lange, Sandra; Bornmann, Sarah; Kock, Holger; Schulze, Lara; Klinger-König, Johanna; Böhm, Susanne; Vogelgesang, Antje; von Podewils, Felix; Föel, Agnes; Gross, Stefan; Wenzel, Katrin; Wallukat, Gerd; Prüss, Harald; Dressel, Alexander; Kunze, Rudolf; Grabe, Hans J.; Langner, Sönke; Dörr, Marcus
  • Erschienen: MDPI AG, 2020
  • Erschienen in: Journal of Clinical Medicine
  • Sprache: Englisch
  • DOI: 10.3390/jcm9061919
  • ISSN: 2077-0383
  • Schlagwörter: General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p>Background: agonistic autoantibodies (agAABs) against G protein-coupled receptors (GPCR) have been linked to cardiovascular disease. In dementia patients, GPCR-agAABs against the α1- and ß2-adrenoceptors (α1AR- and ß2AR) were found at a prevalence of 50%. Elimination of agAABs by immunoadsorption (IA) was successfully applied in cardiovascular disease. The IMAD trial (Efficacy of immunoadsorption for treatment of persons with Alzheimer dementia and agonistic autoantibodies against alpha1A-adrenoceptor) investigates whether the removal of α1AR-AABs by a 5-day IA procedure has a positive effect (improvement or non-deterioration) on changes of hemodynamic, cognitive, vascular and metabolic parameters in patients with suspected Alzheimer’s clinical syndrome within a one-year follow-up period. Methods: the IMAD trial is designed as an exploratory monocentric interventional trial corresponding to a proof-of-concept phase-IIa study. If cognition capacity of eligible patients scores 19–26 in the Mini Mental State Examination (MMSE), patients are tested for the presence of agAABs by an enzyme-linked immunosorbent assay (ELISA)-based method, followed by a bioassay-based confirmation test, further screening and treatment with IA and intravenous immunoglobulin G (IgG) replacement. We aim to include 15 patients with IA/IgG and to complete follow-up data from at least 12 patients. The primary outcome parameter of the study is uncorrected mean cerebral perfusion measured in mL/min/100 gr of brain tissue determined by magnetic resonance imaging with arterial spin labeling after 12 months. Conclusion: IMAD is an important pilot study that will analyze whether the removal of α1AR-agAABs by immunoadsorption in α1AR-agAAB-positive patients with suspected Alzheimer’s clinical syndrome may slow the progression of dementia and/or may improve vascular functional parameters.</jats:p>
  • Zugangsstatus: Freier Zugang